Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 25;17(7):1104.
doi: 10.3390/cancers17071104.

Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine

Zoi Tsakiraki  1 , Aris Spathis  1 , Anthi Bouchla  2 , Abraham Pouliakis  1 , Pinelopi Vryttia  2 , Ioannis G Panayiotides  1 , Vasiliki Pappa  2 , Sotiris G Papageorgiou  2 , Periklis G Foukas  1
Affiliations

Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine

Zoi Tsakiraki et al. Cancers (Basel). .

Abstract

Background/objectives: There are limited data regarding immunohistochemical profiling of immune cells in bone marrow trephine biopsies of patients with high-risk myelodysplastic syndromes (HR-MDS).

Methods: We sought to objectively quantify, with the use of digital pathology, the density (cells/mm2) of the prominent adaptive immunity cell populations in sixty-four (64) bone marrow trephine biopsies of HR-MDS patients receiving 5-Azacytidine. We focused on CD3(+) T cells, CD8(+) cytotoxic T cells (Tc), helper T cells (Th), Foxp3(+) regulatory T cells (Tregs), CD20(+) B-cells and CD138(+) plasma cells and evaluated the presence and the number of lymphoid aggregates. A control group of twenty "non-MDS" patients was included in the study.

Results: We identified a significant decrease in adaptive immune cell densities in the HR-MDS patients compared to the non-MDS controls. Increased T and Th cell densities correlated with the response to 5-Azacytidine (5-AZA) treatment. Higher T, Tc, Th and plasma cells densities and low B, Tregs and Tregs/T cells ratios correlated with increased overall survival. Reduced Tregs, Tregs/T cells, Tregs/Tc and plasma cells showed improved leukemia-free survival. A modified IPSS-R (IPSS-R-I), combining the initial IPSS-R with the immune populations' parameters, improved overall survival and showed a double-fold increase in Cox calculated hazard ratios.

Conclusions: Immunohistochemical bone marrow immune profiling represents a powerful and easily useable tool for investigating the possible role of bone marrow immune microenvironment in the pathogenesis and progression of MDS, but also its association with the response to 5-AZA treatment and clinical outcomes.

Keywords: 5-Azacitidine; digital pathology; immunoenvironment; immunohistochemistry; myelodysplastic syndromes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(A) The five areas (R1–R5) with the highest densities of CD8+ cytotoxic T cells were selected (2× magnification left, 20× magnification right). Our metric procedure included bone marrow cellularity normalization by deducting bone and fat tissue areas as well as any artifactual empty spaces. The density of each immune cell population was calculated as the mean of the five different areas normalized per mm2 and 100% BM cellularity. (B) The same areas were chosen for the estimation of CD3, CD20, CD138 and FOXP3. These are some examples that illustrate the variability of the density (high and low) of these immune populations (40× magnification).
Figure 2
Figure 2
The densities (mean value/mm2 of bone marrow) of the immune cell populations according to WHO-defined entities. Individuals from the control group are also included.
Figure 3
Figure 3
Kaplan–Meier curves showing the overall survival (upper panel) and leukemia-free survival (lower panel) according to both the IPSS-R groups and the newly proposed IPSS-R-I groups.
See this image and copyright information in PMC

References

    1. Banerjee T., Calvi L.M., Becker M.W., Liesveld J.L. Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes. Blood Rev. 2019;36:57–69. doi: 10.1016/j.blre.2019.04.004. - DOI - PMC - PubMed
    1. Fozza C., Crobu V., Isoni M.A., Dore F. The immune landscape of myelodysplastic syndromes. Crit. Rev. Oncol. Hematol. 2016;107:90–99. doi: 10.1016/j.critrevonc.2016.08.016. - DOI - PubMed
    1. Winter S., Shoaie S., Kordasti S., Platzbecker U. Integrating the “Immunome” in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design. J. Clin. Oncol. 2020;38:1723–1735. doi: 10.1200/jco.19.01823. - DOI - PubMed
    1. Kouroukli O., Symeonidis A., Foukas P., Maragkou M.K., Kourea E.P. Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. Cancers. 2022;14:5656. doi: 10.3390/cancers14225656. - DOI - PMC - PubMed
    1. Kordasti S.Y., Afzali B., Lim Z., Ingram W., Hayden J., Barber L., Matthews K., Chelliah R., Guinn B., Lombardi G., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br. J. Haematol. 2009;145:64–72. doi: 10.1111/j.1365-2141.2009.07593.x. - DOI - PubMed

LinkOut - more resources